A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of 28-Day Oral Dosing of RVX000222 in Healthy Subjects and Subjects With Low High Density Lipoprotein (HDL)

Trial Profile

A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of 28-Day Oral Dosing of RVX000222 in Healthy Subjects and Subjects With Low High Density Lipoprotein (HDL)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Jul 2016

At a glance

  • Drugs Apabetalone (Primary)
  • Indications Atherosclerosis; Low HDL cholesterol
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Resverlogix Corporation
  • Most Recent Events

    • 22 Jun 2010 Data presented at the European Atherosclerosis Society Congress, according to a Resverlogix media release.
    • 03 Feb 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
    • 29 Sep 2009 Status changed from recruiting to completed, according to a Resverlogix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top